Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque

Patent Citations (37)

Non-Patent Literature (106)

• Agatson, A.S., et al., “Quantification of coronary artery calcium using ultrafast computed tomography,” J. Am. Coll. Cardiol., Mar. 15, 1990, 15(4), 827-832.Applicant
• Alderman, E.L., et al., “Five-yar angiographic follow-up of factors associated with progression of coronary artery disease in the coronary artery surgery study (CASS),” J. Am. Coll. Cardiol., Oct. 1993, 22(4), 1141-1154.Applicant
• Ambrose, J.A., et al., “Angiographic progression of coronary artery disease and the development of myocardial infarction,” J. Am. Coll. Cardiol., Jul. 1988, 12(1), 56-62.Applicant
• Ambrose, J.A., “ Angiographic correlations of advanced coronary lesions in acute coronary syndromes,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.), Futura Publishing Co., Inc., 1996, 105-122.Applicant
• Anderson, C.J., et al., “Radiometal-labeled agents (non-technetium for diagnostic imaging,” Chem. Rev., 1999, 99(9), 2219-2234.Applicant
• Anson, F.C., et al., “Interconversion of planar and nonplanar N-amido ligands. Thermodynamically stable nonplanar N-anudi kugabdsm” J. Am. Chem. Soc., 1996, 108(21), 6593-6605.Applicant
• Antopolsky, M., et al., “Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties,” Bioconjugate Chem., 1999, 10, 598-606.Applicant
• Atsma, D.E., et al., “Potential of 99mTc-LDLs labeled by two different methods for scintigraphic detection of experimental atherosclerosis in rabbits,” Arteroscler and Thromb, Jan. 1993, 13(1), 78-83.Applicant
• Barrington, S.F., “Clinical use of PET in neurology,” Nucl. Med. Commun., Mar. 2000, 21(3), 237-240.Applicant
• Bar-Shalom, R., et al., “PET imaging in oncology,” Seminars in Nucl. Med., Jul. 2000, 30(3), 150-185.Applicant
• Baumgartener, H.-R., et al., “Eine neue methode zur erzeugung von thrombin durch gezielte Überdehnung der gefäβwand,” Gesamte Exp. Med., 1963, 137, 227-249 (German).Applicant
• Bayley, H., “Protein therapy—delivery guaranteed,” Nat. Biotechnol., Nov. 1999, 17(11), 1066-1067.Applicant
• Becker, C.R., et al., “Visualization and quantification of coronary calcifications with electron beam and spiral computed tomogramphy,” Eur. Radiol., 2000, 10, 629-635.Applicant
• Bhorde, R., et al., “Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat derived membrane translocation peptide,” Bioconjugate Chem., May/Jun. 2000, 11(3), 301-305.Applicant
• Bousquet, J.-C., et al., “Characterization of a new paramagnetic complex1,” Radiology, Mar. 1988, 166(3), 693-698.Applicant
• Brechbiel, M.W., et al., “Backbone-substituted DTPA ligands for 90Y radioimmunotherapy,” Bioconjugate Chem., 1991, 2, 187-194.Applicant
• Brechbiel, M.W., et al., “synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA, antibody labeling and tumor-imaging studies,” Inorg. Chem., 1987, 25, 2772-2781.Applicant
• Brundage, B.H., et al., “The calcium story and electron beam computed tomography,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.), Futura Publishing Co., Inc., 1996, 417-427.Applicant
• Budoff, M.J., et al., “Rates of progression of coronary calcium by electron beam tomography,” Am. J. Cardiol., Jul. 1, 2000, 86, 8-11.Applicant
• Caravan, P., et al., “Gadolinium(III) chelates as MRI contract agents: structure, dynamics, and applications,” Am. Chem. Soc., 1999, 99(9), 2293-2352.Applicant
• Carrington, C., “Could coronary calcium screening prevent this?,” Diagnostic Imaging, Apr. 2000, 48-53.Applicant
• Cerqueira, M.D., et al., “Current status of radionuclide tracer imaging of thrombi and atheroma,” Seminars in Nucl. Med., W.B. Saunders Co.,, Oct. 1999, 29(4), 339-351.Applicant
• Cooper, E.S., “Prevention: the key to progress; President's address to the 65th scientific sessions of the American Heart Association,” Circulation, Apr. 1993, 87(4), 1430-1433.Applicant
• Delbeke, D., “Oncological applications of FDG PET imaging,” J. Nucl. Med., Oct. 1999, 40(10), 1706-1715.Applicant
• Dinsmore, R.E., et al., “Imaging techniques in carotid and peripheral vascular disease,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.), Futura Publishing Co., Inc., 1996, 277-289.Applicant
• Doherty, T.M., et al., “Coronary calcium: the good, the bad, and the uncertain,” Am. Heart J., May 1999, 137, 806-814.Applicant
• Doyle, M., et al., “Magnetic resonance coronary artery imaging,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.), Futura Publishing Co., Inc., 1996, 313-332.Applicant
• Duncan, K., “Radiopharmaceuticals in PET imaging,” J. of Nucl. Med. Technol., 1998, 26, 228-234.Applicant
• Elmaleh, D.R., et al., “Rapid noninvasive detection of experimental atherosclerotic lesions with novel 99mTc-labeled diadenosine tetraphosphates,” Proc. Natl. Acad. Sci. USA, Jan. 1998, 95, 691-695.Applicant
• Erbel, R., et al., “Electron-beam computed tomography for detection of early signs of coronary arteriosclerosis,” Eur. Heart J., 2000, 21, 720-732.Applicant
• Farb, A., et al., “Sudden coronary death,” Circulation, 1995, 92, 1701-1709.Applicant
• Fawell, S., et al., “Tat-mediated delivery of heterologous proteins into cell,” Proc. Natl. Acad. Sci. USA, Jan. 1994, 91, 664-668.Applicant
• Freeman, M., et al., “Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein,” Proc. Natl. Sci. USA, Jun. 1991, 88, 4931-4935.Applicant
• Fuster, V., et al., “The pathogenesis of coronary artery disease and the acute coronary syndromes,” N. Engl. J. Med., Jan. 23, 1992, Epstein, F.H. (Ed.), 326, 242-250.Applicant
• Galis, Z.S., et al., “Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases,” Proc. Acad. Sci. USA, Jan. 1995, 92, 402-406.Applicant
• Glover, G.D., et al., “Research directions in MR imaging,” Radiology, 1998, 207, 289-295.Applicant
• Goldstein, J.L., et al., “Receptor-mediated endocytosis of low-density lipoprotein in cultured cells,” Methods in Enzymol., 1983, 98, 241-261.Applicant
• Goldstein, J.L., et al., “Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition,” Proc. Natl. Sci. USA, Jan. 1979, 76(1), 333-337.Applicant
• Goyen, M., et al., “MR-angiography: the role of contrast agents,” Eur. J. Radiol., 2000, 34, 247-256.Applicant
• Grist, T., et al., Nuclear magnetic resonance imaging as applied to carotid and peripheral atherosclerotic vascular disease, Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.), Futura Publishing Co., Inc., 1996, 333-362.Applicant
• Haynes, N.G., et al., “Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM,” J. Nucl. Med., 2000, 41, 309-314.Applicant
• Hnatowich, D.J., et al., “Radioactive labeling of antibody: a simple and efficient method,” Science, 1983, 220, 613-616.Applicant
• Iuliano, L., et al., “Preparation and biodistribution of 99mtechnetium labeled oxidized LDL in man,” Atherosclerosis, Aug. 1996, 126(1), 131-141.Applicant
• Janowitz, W.R., et al., “Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomtic men and women,” Am. J. Cardiol., Aug. 1, 1993, 72(3), 247-254.Applicant
• Josephson, L., et al., “High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates,” Bioconjugate Chem., 1999, 10, 186-191.Applicant
• Jurisson, S.S., et al., “Potential technetium small molecule radiopharmaceuticals,” Chem. Rev., 1999, 99, 2205-2218.Applicant
• Kaski, J.C., et al., “Rapid angiographic progression of coronary artery disease in patients with angina pectoris,” Circulation, 1995, 92, 2058-2065.Applicant
• Knopp, M.V., et al., “Contrast agents for MRA: future directions,” J. Magn. Reson. Imaging, 1999, 10, 314-316.Applicant
• Kohler, T.R., “Imaging of carotid artery lesions: a surgeon's view,” Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology, Fuster, V. (Ed.), Futura Publishing Co., Inc., 1996, 205-223.Applicant
• Krejcarek, G.E., et al., “Covalent attachment of chelating groups to macromolecules,” Biochem. & Biophys. Res. Commun., 1977, 77(2), 581-585.Applicant
• Ku, D.N., et al., “Pulsatile flow and atherosclerosis in the human carotid bifurcation,” Atherosclerosis, May/Jun. 1985, 5, 293-302.Applicant
• Lees, A.M., et al., “Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins,” Arteriosclerosis, Sep./Oct. 1988, 8, 461-470.Applicant
• Lewin, M., et al., “Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells,” Nat. Biotechnol., Apr. 2000, 18, 410-414.Applicant
• Lin, Y.-Z., et al., “Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence,” J. Biol. Chem., 1995, 270(24), 14255-14258.Applicant
• Lindgren, M., et al., “Cell-penetrating peptides,” TiPS, Mar. 2000, 21, 99-103.Applicant
• Little, W.C., et al., “Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease,?” Circulation, 1988, 78, 1157-1166.Applicant
• Liu S., et al., “Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals,” Bioconjugate Chemistry, 2001, 12, 7-34.Applicant
• Liu, S., et al., “99mTc labeling of highly potent small peptides,” Bioconjugate Chem., 1997, 8, 621-636.Applicant
• Liu, S., et al., “99mTc-labeled small peptides as diagnostic radiopharmaceuticals,” Chem. Rev., 1999, 99, 2235-2268.Applicant
• Lysko, P.G., et al., “Identification of a small-molecule, nonpeptide macrophage scavenger receptor antagonist,” J. Pharmacol. Exp. Ther., Jun. 1999, 289(3), 1277-1285.Applicant
• Maisley, M.N., “Clinical PET in cardiology and cardiac surgery,” Nucl. Med. Commun., 2000, 21, 234-236.Applicant
• Margerstadt, M., et al., “Gd(DOTA): an alternative to Gd(DTPA as a T1,2 relaxation agent for NMR imaging or spectroscopy,” Magn. Reson. Med., 1986, 3, 808-812.Applicant
• Marmion, M., et al., “Tracers and contrast agents in cardiovascular imaging: present and future,” J. Nucl. Biol. Med., 1996, 40, 121-131.Applicant
• Mazzone, A., et al., “Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease,” Circulation, 1993, 88, 358-363.Applicant
• McVeigh, E.R., “MRI of myocardial function: motion tracking techniques,” Magn. Reson. Imaging, 1996, 14(2), 137-150.Applicant
• Meaney, J.F.M., et al., “Pulmonary magnetic resonance angiography,” J. Magn. Reson. Imaging, 1999, 10, 326-338.Applicant
• Meares, C.F., et al., “Chelating agents for the binding of metal ions to antibodies,” Nucl. Med. Biol., 1986, 13(4), 311-318.Applicant
• Moi, et al., “Cooper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent,” Anal. Biochem., 1985, 148, 249-253.Applicant
• Moi, M.K., et al., “The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododencane-N,N',N'', N''',N''''-tetraacetic acid and study of its yttrium(III) complex,” J. Am. Chem. Soc., 1988, 110, 6266-6267.Applicant
• Morris, M.C., et al., “A new peptide vector for efficient delivery of oligonucleotides into mammalian cells,” Nucleic Acids Res., 1997, 25(14), 2730-2736.Applicant
• Narula, J., et al., “Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma,” Circulation, 1995, 92, 474-484.Applicant
• Narula, J., et al., :Gamma imaging of atherosclerotic lesions: the role of antibody affinity in in vivo target localization, J. Nucl. Cardiol., 1996, 3, 231-241.Applicant
• Narula, J., “Strategic targeting of atherosclerotic lesions,” J. Nucl. Cardiol., 1999, 6, 81-90.Applicant
• Narula, J., “‘POPE’: Predicting outcome by plaque evaluation,” Nucl. Med. Commun., 2000, 21, 601-608.Applicant
• Nunan, T.O., et al., “PET in oncology II—other tumours,” Nucl. Med. Commun., 2000, 21, 229-233.Applicant
• O'Doherty, M.J., “PET in oncology I—lung, breast, soft tissue sarcoma,” Nucl. Med. Commun., 2000, 21, 224-229.Applicant
• Orford, J.L., et al., “The comparative pathobiology of atherosclerosis and restenosis,” Am. J. Cardiol., 2000, 86 (suppl.), 6H-11H.Applicant
• Patel, M.R., et al., “Preoperative assessment of the carotid bifurcation,” Stroke, 1995, 26, 1753-1758.Applicant
• Phelps, M.E., “PET: the merging of biology and imaging into molecular imaging,” J. Nucl. Med., 2000, 41, 661-681.Applicant
• Polak, J.F., “Focus on imaging at the American Heart Association Annual Meeting,” Radiology, 2000, 216, 323-324.Applicant
• Pooga, M., “Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo,” Nat. Biotechnol., Sep. 1998, 16, 857-861.Applicant
• Remington's Pharmaceutical Sciences, 17th Ed., Mack Publishing Co., Easton, PA, 1985, p. 1418.Applicant
• Ross, R., “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, Apr. 29, 1993, 362, 801-809.Applicant
• Rumberger, J.A., “Electron beam CT and coronary calcium score,” Circulation, 1998, 97, 2095-2097.Applicant
• Runge, V.M., et al., “Safety of approved MR contrast media for intravenous injection,” J. Magnetic Resonance Imaging, 2000, 12, 205-213.Applicant
• Runge, V.M., et al., “MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA,” Radiology, 1988, 166, 835-838.Applicant
• Schluesener, H.J., “Protection against experimental nervous system autoimmune disease by a human immunodeficiency virus-1 Tat peptide-based polyvalent vaccine,” J. of Neurosci. Res., 1996, 46(2), 258-262 (abstract).Applicant
• Schmermund, A., et al., “Usefulness of topography of coronary calcium by electron-beam computed tomography in predicting the natural history of coronary atherosclerosis,” Am. J. Cardiol., Jul. 15, 2000, 86, 127-132.Applicant
• Schwartz, J.J., et al., “Peptide-mediated cellular delivery,” Current Opinions in Molecular Therapeutics, 2000, 2(2), 162-167.Applicant
• Singh, D., et al., “Peptide-based intracellular shuttle able to facilitate gene transfer in mammalian cells,” Bioconjugate Chem., 1999, 10, 745-754.Applicant
• Stern, W., et al., “ Dynamic MR imaging of liver metastases with Gd-EOB-DTPA,” Acta Radiologica, 2000, 41, 255-262.Applicant
• Sutcliffe-Goulden, J.L., et al., “Solid phase synthesis of [18F]labeled peptides for positron emission tomography,” Bioorg. & Med. Chem. Lett., Jul. 2000, 10(14), 1501-1503.Applicant
• Toussaint, J.-F., et al., “T2-weighted contrast for NMR characterization of human atherosclerosis,” Arterioscler. Thromb Vasc Biol., 1995, 15, 1533-1542.Applicant
• Toussaint, J.-F., et al., “Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo,” Circulation, 1996, 94, 932-938.Applicant
• Vaidyanathan, G., et al., “Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents,” Bioconjugate Chem., 1990, 1, 269-273.Applicant
• Vaidyanathan, G., et al., “Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of monoclonal antibody fragment,” Bioconjugate Chem., 1994, 5, 352-356.Applicant
• Vaidyanathan, G., et al., “Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate,” Nucl. Med. Biol., 1992, 19(3), 275-281.Applicant
• Vaidyanathan, G., et al., “Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection,” Nucl. Med. Biol., 1995, 22(6), 759-764.Applicant
• Vallabhajosula, S., et al., “Atherosclerosis: imaging techniques and the evolving role of nuclear medicine,” J. Nucl. Med., Nov. 1997, 38(11), 1788-1796.Applicant
• Virgolini, I., et al., “Autologous low-density lipoprotein labeling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage,” Eur. J. of Nucl. Med., 1991, 18, 948-951.Applicant
• Volkert, W.A., et al., “Therapeutic radiopharmaceuticals,” Chem. Rev., 1999, 99, 2269-2292.Applicant
• Weissleder, R., et al., “Drug targeting in magnetic resonance imaging,” Magnetic Resonance Quarterly, 1992, 8(1), 55-63.Applicant
• Welch, M., et al., :The potential role of generator-produced radiopharmaceuticals in clinical PET, J. Nucl. Med., Feb. 2000, 41(2), 315-317.Applicant
• Wexler, L., et al., “Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications,” Circulation, 1996, 94, 1175-1192.Applicant
• Who-Monica Project, “Myocardial infarction and coronary deaths in the world health organization MONICA project; Registraction procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents,” Circulation, 1994, 90, 583-612.Applicant
• Yuan, C., et al., “Techniques for high-resolution MR imaging of atherosclerotic plaque,” J. of Magn. Reson. Imaging, 1994, 4, 43-49.Applicant